Type 2 diabetes mellitus (DM) is highly prevalent among Asian patients with heart failure (HF)1 and Asians develop HF and DM almost a decade earlier2,3 than their Western counterparts. Co-existence of both conditions carry worse prognosis than either alone, with increased rates of progression to DM-related complications. Anti-diabetic medications are important for glycaemic control.
While some may worsen HF, some newer agents may improve cardiovascular outcomes. Prospective multinational data on concomitant pharmacological management of DM and HF are scarce. We investigated patients with DM and HF with reduced ejection fraction (HFrEF) enrolled in the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry2 to assess the prescription patterns of anti-diabetic and anti-HF medications and to determine the association of anti-diabetic medications with 1-year all-cause mortality or…
